首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

市場調查報告書

商品編碼

1063200

細胞、基因治療製造服務的全球市場(2021年～2028年)

Global Cell & Gene Therapy Manufacturing Services Market - 2021-2028

出版日期: 2022年03月03日 | 出版商:

DataM Intelligence | 英文 175 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球細胞、基因治療製造服務市場相關調查分析，市場動態，產業分析，市場分析，競爭情形等系統性資訊。

簡介
- 市場規模分析，及與前一年同期比較成長分析(%):各類型
- 市場魅力指數:各類型
細胞治療*
- 同種異體
- 自體
- 病毒載體
- 簡介
- 市場規模分析，100萬美元(2019年～2028年)，及與前一年同期比較成長分析(%)(2020年～2028年)
基因治療
- 非病毒載體
- 病毒載體

第8章全球細胞、基因治療製造服務市場:各適應症

簡介
- 市場規模分析，及與前一年同期比較成長分析(%):各適應症
- 市場魅力指數:各適應症
腫瘤疾病*
- 簡介
- 市場規模分析，100萬美元(2019年～2028年)，及與前一年同期比較成長分析(%)(2020年～2028年)
心血管疾病
整形外科疾病
眼科疾病
中樞神經系統障礙
感染疾病
其他

第9章全球細胞、基因治療製造服務市場:各應用領域

簡介
- 市場規模分析，及與前一年同期比較成長分析(%):各應用領域
- 市場魅力指數:各應用領域
臨床製造*
- 簡介
- 市場規模分析，100萬美元(2019年～2028年)，及與前一年同期比較成長分析(%)(2020年～2028年)
商業生產

第10章全球細胞、基因治療製造服務市場:各終端用戶

簡介
- 市場規模分析，及與前一年同期比較成長分析(%):各終端用戶
- 市場魅力指數:各終端用戶
製藥及生物科技企業*
- 簡介
- 市場規模分析，100萬美元(2019年～2028年)，及與前一年同期比較成長分析(%)(2020年～2028年)
學術機構、研究機關
其他

第11章全球細胞、基因治療製造服務市場:各地區

簡介
- 市場規模分析，100萬美元(2019年～2028年)，及與前一年同期比較成長分析(%)(2020年～2028年):各地區
- 市場魅力指數:各地區
北美
歐洲
南美
亞太地區
中東和非洲

第12章全球細胞、基因治療製造服務市場-競爭情形

主要的開發與策略
企業佔有率分析
產品的基準
值得注意的主要企業的清單

第13章全球細胞、基因治療製造服務市場-企業簡介概要

Charles River Laboratories*
- 企業概要
- 產品系列及說明
- 主要亮點
- 財務概要
Thermo Fisher Scientific Inc.
Lonza
Merck KGaA
Catalent, Inc.
Takara Bio Inc.
FUJIFILM Irvine Scientific
F. Hoffmann-La Roche Ltd.
Oxford Biomedica plc.
BioCentriq

第14章全球細胞、基因治療製造服務市場-DataM

附錄
關於本公司、應用
諮詢方式

簡介目錄

Product Code: DMBT4829

Market - Overview

The global cell & gene therapy manufacturing services market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Cell and gene therapies are intended to stop or reverse disease progression. They are frequently one-time treatments that can cure specific ailments by alleviating the underlying cause of disease. Cell and gene therapies are a niche product area. They have been a recent active area of investment by both pharmaceutical companies to add products to the pipeline and manufacturing capabilities and by certain contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) to add cell-therapy manufacturing capabilities to their toolbox.

Market Dynamics

Increasing research and development of cell and gene therapy products in pharmaceutical and biotechnology companies is expected to drive market growth.

ElevateBio shares some parallels with The Discovery Labs, another innovative service firm. BioCentriq, a university-based services organization already operating in New Jersey, would better compare the Philadelphia-area venture. These three firms and others like them are targeting the booming cell and gene therapy market with their services. They are assisting in creating a completely new branch of the pharmaceutical CDMO world in the process. Moreover, Only seven cell and gene therapy medications have been licensed by the US Food and Drug Administration. Still, more than 1,200 investigational therapies are in the pipeline, with more than half in Phase 2 clinical trials. Annual sales growth is expected to be over 15% for cell therapies and approximately 30% for gene therapies. And the number of companies developing cell and gene therapies is fast increasing; the Alliance for Regenerative Medicine predicts 1,100 such companies in 2020, up 10% from 2019. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Cell and gene therapy production has substantial operating costs. For instance, The cost of goods/manufacturing alone for a gene treatment can range from $500,000 to $1 million. It doesn't include R&D, clinical trial costs, or the price of establishing the commercial infrastructure needed to enable access to patients. Therefore, the market is expected to hamper market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic resulted in control measures that impacted life science operations, including production and research. The CEO of Flagship Pioneering (US) indicated in an article published by Nature Biotechnology that lab productivity at many of its research-based settings was just 30-50 percent. Maintaining that rate was a difficulty. Moreover, hundreds of relevant clinical trials are currently underway worldwide. Numerous research facilities implemented protocols limiting the number of lab employees allowed on-site to reduce the risk of virus transmission, putting many investigations on hold. For instance, The stoppage of patient enrolment caused about 61 percent of clinical studies to be halted. Thus, the market will undergo impetus growth during the forecast period.

Segment Analysis

Cell Therapy segment is expected to hold the largest market share in cell & gene therapy manufacturing services market

The cell therapy segment is expected to dominate in 2020. Raising cell therapy awareness, increasing demand for cell therapy, increasing financing for new cell lines, expanding collaborations and acquisitions, and developing improved genomics tools for cell analysis are factors that the market is expected to boost in the forecast period. For instance, Cell therapies that are allogeneic or universal rely on a single source of cells to treat many patients. To construct a master cell bank, cells are taken from a donor sample (MCB). The MCB is then utilized as a source to generate cell populations treated according to the therapy's requirements. Moreover, Most CAR cell therapies, including the FDA-approved products, are generated using autologous T cells. It has several important advantages, including infusion of CAR-engineered cell products without immunologic mismatch between donor and recipient.

Additionally, Allogene Therapeutics, a clinical-stage biotechnology firm based in South San Francisco, California that develops allogeneic CAR T therapies for cancer, signed a lease deal in February 2019 to establish a 118,000-square-foot cell-therapy production facility in Newark, California. The facility is used to produce allogeneic CAR T treatments, which are patented. Thus, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global cell & gene therapy manufacturing services market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of cancer and clinical trials carried out by the market players and well-established healthcare facilities in the region are a few factors the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. In contrast, In 2020, an estimated 1,806,590 new cancer cases were diagnosed in the United States, and 606,520 people died from the disease. The three most common cancers for women are breast, lung, and colorectal, and they will account for an estimated 50% of all new cancer diagnoses in 2020.

Moreover, considerable part is by an increase in research and development activities and the availability of favorable healthcare infrastructure. For instance, According to a research titled Profitability of Large Pharmaceutical Companies Compared With Other Large Companies," published in March 2020, biotech companies earned USD 15.9 billion in the first three quarters of 2020, compared to USD 13.5 billion in the same period of 2018. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the cell & gene therapy manufacturing services market are Charles River Laboratories, Thermo Fisher Scientific Inc., Lonza, Merck KGaA, Catalent, Inc., Takara Bio Inc., FUJIFILM Irvine Scientific, F. Hoffmann-La Roche Ltd., Oxford Biomedica plc. and BioCentriq

BioCentriq:

Overview:

BioCentriq was founded in 2018 and is a full-service CDMO for cell and gene therapy process development and clinical manufacturing. An ISO-7 certified GMP clinical manufacturing facility is in Newark, NJ. The company manufactures autologous and allogeneic cell therapies gene therapies at this facility and provides analytical and quality services across several cell types. Moreover, it also offers viral vector production, cell and viral banking and upstream and downstream processing. Additionally, it can manufacture immunotherapies, including monoclonal antibodies and proteins and vaccines. The facilities provide full customer access to hybrid teams from tech transfer through GMP clinical production. BioCentriq has a BSL-2 certified process development facility in South Brunswick, NJ, to accelerate scale-up and translation activities.

Product Portfolio:

The company offers cell and gene therapy development and optimization, a dedicated scientific team with significant experience in the field, suspension and adherent cell culture capability, optimization: cell growth, vector selection, yield and R&D process replication with open to closed system transformation and optimization.

Why Purchase the Report?

Visualize the composition of the cell & gene therapy manufacturing services market segmentation by type, indication, application, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in cell & gene therapy manufacturing services market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of cell & gene therapy manufacturing services market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global cell & gene therapy manufacturing services market report would provide an access to an approx. 45+market data table, 40+figures and 175 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Cell & Gene Therapy Manufacturing Services Market - By Type

Cell Therapy

Allogeneic

Autologous

Viral Vector

Gene Therapy

Non-viral Vectors

Viral Vectors

Global Cell & Gene Therapy Manufacturing Services Market - By Indication

Oncology Diseases

Cardiovascular Diseases

Orthopedic Diseases

Ophthalmology Diseases

Central Nervous System Disorders

Infectious Diseases

Others

Global Cell & Gene Therapy Manufacturing Services Market - By Application

Clinical Manufacturing

Commercial Manufacturing

Global Cell & Gene Therapy Manufacturing Services Market - By End user

Pharmaceutical and Biotechnology Companies

Academic and Research Institutes

Others

Global Cell & Gene Therapy Manufacturing Services Market - By Region

North America

South America

Europe

Asia

Middle East & Africa

1. Global Cell & Gene Therapy Manufacturing Services Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Global Cell & Gene Therapy Manufacturing Services Market - Market Definition and Overview

3. Global Cell & Gene Therapy Manufacturing Services Market - Executive Summary

3.1. Market Snippet by Type
3.2. Market Snippet by Indication
3.3. Market Snippet by Application
3.4. Market Snippet by End User
3.5. Market Snippet by Region

4. Global Cell & Gene Therapy Manufacturing Services Market - Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing research and development of cell and gene therapy products in pharmaceutical and biotechnology companies is expected to drive market growth.
- 4.1.2. Restraints:
  - 4.1.2.1. The high operating costs of cell and gene therapy manufacturing are expected to hamper the market growth.
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Global Cell & Gene Therapy Manufacturing Services Market - Industry Analysis

5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Unmet Needs

6. Global Cell & Gene Therapy Manufacturing Services Market - COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. Global Cell & Gene Therapy Manufacturing Services Market - By Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type Segment
7.2. Cell Therapy*
- 7.2.1. Allogeneic
- 7.2.2. Autologous
- 7.2.3. Viral Vector
- 7.2.4. Introduction
- 7.2.5. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Gene Therapy
- 7.3.1. Non-viral Vectors
- 7.3.2. Viral Vectors

8. Global Cell & Gene Therapy Manufacturing Services Market - By Indication

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
- 8.1.2. Market Attractiveness Index, By Indication Segment
8.2. Oncology Diseases*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Cardiovascular Diseases
8.4. Orthopedic Diseases
8.5. Ophthalmology Diseases
8.6. Central Nervous System Disorders
8.7. Infectious Diseases
8.8. Others

9. Global Cell & Gene Therapy Manufacturing Services Market - By Application

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application Segment
9.2. Clinical Manufacturing*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Commercial Manufacturing

10. Global Cell & Gene Therapy Manufacturing Services Market - By End user

10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 10.1.2. Market Attractiveness Index, By End user Segment
10.2. Pharmaceutical and Biotechnology Companies*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Academic and Research Institutes
10.4. Others

11. Global Cell & Gene Therapy Manufacturing Services Market - By Region

11.1. Introduction
- 11.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
- 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
- 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Cell & Gene Therapy Manufacturing Services Market - Competitive Landscape

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of Key Companies to Watch

13. Global Cell & Gene Therapy Manufacturing Services Market- Company Profiles

13.1. Charles River Laboratories*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Key Highlights
- 13.1.4. Financial Overview
13.2. Thermo Fisher Scientific Inc.
13.3. Lonza
13.4. Merck KGaA
13.5. Catalent, Inc.
13.6. Takara Bio Inc.
13.7. FUJIFILM Irvine Scientific
13.8. F. Hoffmann-La Roche Ltd.
13.9. Oxford Biomedica plc.
13.10. BioCentriq

LIST NOT EXHAUSTIVE